Navigation Links
Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Date:10/27/2008

owing administration of a single dose of TRU-015 at six-month intervals along with B-cell depletion and recovery following re-treatment, comparable to results seen after initial treatment.

Results from the Phase 1/2a re-treatment study also indicated total serum IgG levels were relatively preserved. In addition, subjects treated with three or more courses of therapy experienced persistent decreases in rheumatoid factor and IgM levels. Re-treatment with TRU-015 did not result in an increase in any adverse events compared with the initial infusion, and the re-treatment infusions were well-tolerated. No neutralizing antibodies to TRU-015 had been detected at the time of this assessment.

TRU-015 Phase 2b Re-treatment Data

A separate Phase 2b study (15002) is also ongoing. The initial treatment results were presented last year. Re-treatment data from study 15002 were not available in time to present at ACR but will be submitted for presentation in a future peer-reviewed forum. The objective of the two ongoing re-treatment studies is to evaluate the safety; tolerability; pharmacodynamics (PD), specifically, B-cell depletion over time; pharmacokinetics; and immunogenicity of repeat doses of TRU-015 for RA following initial administration.

Two hundred and forty patients entered the open-label re-treatment portion of the Phase 2b study (15002) and received 800 mg of TRU-015. Data was available for all 240 patients at the time of this evaluation, of which 204 patients were rheumatoid factor (RF) positive. Under the study protocol, the efficacy endpoint was based on all randomized RF-positive subjects who received any portion of study drug.

Based on the initial treatment results from studies 15001 and 15002, the selected dose for re-treatment in 15002 and additional studies is 800 mg. Preliminary analyses demonstrate that at 24 weeks, ACR 20, 50 and 70 response rates for patients in the initial 800 mg dose group (n=43) who were subsequently r
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
2. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
3. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
4. Trubion Announces Presentations at April/May Investor Conferences
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
10. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
11. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
(Date:7/10/2014)... study published today in the journal PNAS (Proceedings ... that time of day and sleep deprivation have a ... crucial when looking at the best time of day ... disease, and for administering medicines effectively. , Researchers from ... Research, London, investigated the links between sleep deprivation, body ...
(Date:7/10/2014)... have shelled out for crude 3-D glasses, polarized ... experience. These basic devices, used to trick the ... soon be rendered obsolete with the introduction of ... researchers. , TAU doctoral students Yuval Yifat, Michal ... holography based on nanoantennas that could be used ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... (Pink Sheets: BSTC.PK) today announced that it sold,200,000 ... private placement,offering to an investment fund, at a ... to the Company of $2,100,000., About BioSpecifics ... biopharmaceutical company that has,developed and licensed injectable collagenase ...
... is seeking nominations for the Third Annual Greater ... March 18, 2008. Those,interested in nominating a company ... The four award categories are: Entrepreneurial, Best ... Award. Nominators will,be asked to submit documentation and ...
... multiplexing module, SANTA ROSA, Calif., Jan. 14 ... provider of optical components for industrial,applications, is to ... technology. The compact LED combining module, which utilizes,proprietary ... medical instrumentation. The ZoroLight LED module will be,on ...
Cached Biology Technology:Bookham to Enter Biomedical Illumination Market 2Bookham to Enter Biomedical Illumination Market 3
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... new study has revealed that mother birds can provide ... sired with their non-social partner (known as extra-pair offspring). ... birds commonly mate with males other than their social ... interloper,s ,extra pair, offspring often outperform their half brothers ...
... Technology for the first time have shown the earliest ... formation of bones, teeth and sea shells. ... capture a three-dimensional image of the nanoparticles that form ... greater understanding of the formation of bones, teeth and ...
... in US women of childbearing age, and is common in ... in the vagina is disrupted and replaced by an overgrowth ... increased risk for a variety of complications, such as preterm ... be prevented. Vitamin D may play a role in BV ...
Cached Biology News:Mothers give interloper's offspring a head start in life 2Mothers give interloper's offspring a head start in life 3Focus on the formation of bones, teeth and shells 2Vitamin D insufficiency linked to bacterial vaginosis in pregnant women 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... provide fast and reliable automation for ... drug development laboratories. Staccato Mini-Workstations offer ... automate basic liquid handling and material ... with either Caliper's time proven CLARA™ ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Fermentation System to achieve high ... and maximum information output 4 ... precision with small-scale requirements provides users ... with E.coli, Pichia pastoris, yeast, fungi ...
Biology Products: